Sortina Pharma, a pioneer in developing next-generation therapies for cancer proudly announces the appointment of leading neuro-oncologist Professor Petra Hamerlik to its Scientific Advisory Board. With an eminent career marked by groundbreaking contributions to neuro-oncology, Petra’s expertise will play a pivotal role in advancing Sortina’s mission to transform the treatment landscape for aggressive cancers like glioblastoma.
Petra brings a wealth of experience from the University of Copenhagen and the University of Manchester as well as AstraZeneca, establishing a reputation as a thought leader in the field. Her deep understanding of the clinical challenges and opportunities in neuro-oncology aligns perfectly with Sortina’s vision of delivering life-saving treatments to patients with limited options.
Read more here